Pharmaceuticals company Orchid Pharma announced H1FY25 results H1FY25 Financial Highlights: Sales reached Rs 222.7 crore, with EBITDA at Rs 37.5 crore. Cumulative sales amounted to Rs 467.1 crore, a notable 22% YoY increase compared to H1FY24. EBITDA for H1 rose to Rs 78.6 crore. Manish Dhanuka, Managing Director, Orchid Pharma said: “Our growth is a testament to disciplined operational execution and the momentum from our strategic business development initiatives like the newly launched Orchid AMS. The positive trajectory is proof of our commitment to driving sustainable, profitable growth.” Result PDF
Conference Call with Orchid Pharma Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.